Enlivex Therapeutics Ltd.
Combination immune therapy and cytokine control therapy for cancer treatment
Last updated:
Abstract:
Compositions disclosed herein, and methods of use thereof included those for treating or preventing sepsis in a subject in need, including methods of extending of the survival of a subject suffering from sepsis, and reduction of organ dysfunction or failure due to sepsis. Methods of treating or preventing sepsis in a subject in need includes administering compositions comprising early apoptotic cells or early apoptotic cell supernatants. Compositions and methods of use thereof may reduce the negative proinflammatory effect accompanying sepsis. Further, anti-inflammatory cytokine release may be reduced. In certain instances, compositions may include additional agents.
Status:
Grant
Type:
Utility
Filling date:
4 Nov 2019
Issue date:
3 May 2022